Cited by 10,119Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesChronic Myeloid Leukemia Treatments

The DOI matches its Crossref record; 136 of the 139 references it cites were found in a registry or an index.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Open access

Arber, Daniel A., Orazi, Attilio, Hasserjian, Robert, Thiele, Jürgen, Borowitz, Michael J., Le Beau, Michelle M., Bloomfield, Clara D., Cazzola, Mario, Vardiman, James W.·2016·Blood

DOI 10.1182/blood-2016-03-643544

Open this paper in CoChat — free account Open PDF

Abstract

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2016-03-643544

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit‐MacDonald, A., Harris, N. L., Beau, M. M. L., Hellström‐Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,532
Self-citation
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Acute Myeloid Leukemia
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,468
Self-citation
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,224
Self-citation
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 2,011
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,990
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Self-citation
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
Grimwade, D. J., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., & Burnett, A. K. (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,936
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Self-citation
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596 · cited 1×
“Myeloidassociated gene mutations, such as FLT3, NRAS/KRAS, DNMT3A, IDH1, and IDH2, are reported at high frequency in ETP ALL,(129,130) whereas more typical T-ALL–associated mutations such as activating mutations in NOTCH1 or mutations in CDKN1/2 are infrequent.(131) Although initial small series of ETP ALL suggested t…”
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. (2014) · Leukemia · doi:10.1038/leu.2013.336 · Cited by 1,532
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Self-citation
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Roberts, K. G., Li, Y., Payne-Turner, D., Harvey, R. C., Yang, Y., Pei, D., McCastlain, K., Ding, L., Lu, C. S., Song, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403088 · Cited by 1,369
Self-citation
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
Self-citation
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Núñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,114
Self-citation
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
Coustan‐Smith, E., Mullighan, C. G., Onciu, M. M., Behm, F. G., Raimondi, S. C., Pei, D., Cheng, C., Su, X., Rubnitz, J. E., Basso, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70314-0 · Cited by 1,012
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
den Boer, M. L., van Slegtenhorst, M., de Menezes, R. X., Cheok, M. H.-C., Buijs-Gladdines, J. G. C. A. M., Peters, S. T. C. J. M., van Zutven, L. J. C. M., Beverloo, H. B., van der Spek, P. J., Escherich, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70339-5 · Cited by 927
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Tefferi, A., Guglielmelli, P., Larson, D. R., Finke, C. M., Wassie, E. A., Pieri, L., Gangat, N., Fjerza, R., Belachew, A. A., Lasho, T. L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-579136 · Cited by 748
Self-citation
The genomic landscape of hypodiploid acute lymphoblastic leukemia
Holmfeldt, L., Wei, L., Díaz-Flores, E., Walsh, M. F., Zhang, J., Ding, L., Payne-Turner, D., Churchman, M. L., Andersson, A., Chen, S.-C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2532 · Cited by 738
Self-citation
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
Roberts, K. G., Morin, R. D., Zhang, J., Hirst, M., Zhao, Y., Su, X., Chen, S.-C., Payne-Turner, D., Churchman, M. L., Harvey, R. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.005 · Cited by 706
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Schanz, J., Tüchler, H., Solé, F. G., Mallo, M., Luño, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6394 · Cited by 688
A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia
Gröschel, S., Sanders, M. A., Hoogenboezem, R., de Wit, E., Bouwman, B. A. M., Erpelinck, C., van der Velden, V. H. J., Havermans, M., Avellino, R., van Lom, K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.019 · Cited by 687
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome
Wouters, B. J., Löwenberg, B., Erpelinck-Verschueren, C. A. J., van Putten, W. L. J., Valk, P. J. M., & Delwel, R. (2009) · Blood · doi:10.1182/blood-2008-09-179895 · Cited by 577
Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia
Harvey, R. C., Mullighan, C. G., Chen, I., Wharton, W., Mikhail, F. M., Carroll, A. J., Kang, H., Liu, W., Dobbin, K. K., Smith, M. A., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245944 · Cited by 568
Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
Maxson, J. E., Gotlib, J., Pollyea, D., Fleischman, A. G., Agarwal, A., Eide, C., Bottomly, D., Wilmot, B., McWeeney, S., Tognon, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214514 · Cited by 568
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Itzykson, R., Kosmider, O., Renneville, A., Gelsi‐Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne‐Rauzy, O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3314 · Cited by 559
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Barbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Rodeghiero, F., dʼAmore, E. S. G., Randi, M. L., Bertozzi, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5298 · Cited by 534
Self-citation
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
Malcovati, L., Papaemmanuil, E., Bowen, D., Boultwood, J., Porta, M. G. D., Pascutto, C., Travaglino, E., Groves, M. J., Godfrey, A. L., Ambaglio, I., et al. (2011) · Blood · doi:10.1182/blood-2011-09-377275 · Cited by 506
Self-citation
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8576 · Cited by 463
RUNX1Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
Gaidzik, V. I., Bullinger, L., Schlenk, R. F., Zimmermann, A., Röck, J., Paschka, P., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7926 · Cited by 462
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
Bejar, R. L., Stevenson, K. E., Caughey, B. A., Abdel-Wahab, O. I., Steensma, D. P., Galili, N., Raza, A., Kantarjian, H. M., Levine, R. L., Neuberg, D. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7379 · Cited by 450
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Malcovati, L., Karimi, M., Papaemmanuil, E., Ambaglio, I., Jädersten, M., Jansson, M., Elena, C., Gallì, A., Walldin, G., Della Porta, M. G., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633537 · Cited by 434
Self-citation
Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)
Niemeyer, C. M., Aricò, M., Basso, G., Biondi, A., Rajnoldi, A. C., Creutzig, U., Haas, O. A., Harbott, J., Hasle, H., Kerndrup, G. B., et al. (1997) · PubMed · doi:10.1182/blood.v89.10.3534 · Cited by 405
Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation
Bejar, R. L., Stevenson, K. E., Caughey, B. A., Lindsley, R. C., Mar, B. G., Stojanov, P., Getz, G. A., Steensma, D. P., Ritz, J., Soiffer, R. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3381 · Cited by 403
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
Piazza, R., Valletta, S., Winkelmann, N., Redaelli, S., Spinelli, R., Pirola, A., Antolini, L., Mologni, L., Donadoni, C., Papaemmanuil, E., et al. (2012) · Nature Genetics · doi:10.1038/ng.2495 · Cited by 400
The landscape of somatic mutations in Down syndrome–related myeloid disorders
Yoshida, K., Toki, T., Okuno, Y., Kanezaki, R., Shiraishi, Y., Sato‐Otsubo, A., Sanada, M., Park, M.-J., Terui, K., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2759 · Cited by 393
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations
Tang, J., Hou, H., Chen, C., Liu, C., Chou, W., Tseng, M., Huang, C., Lee, F., Liu, M.-C., Yao, M., et al. (2009) · Blood · doi:10.1182/blood-2009-05-223784 · Cited by 355
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
Gisslinger, H., Gotić, M., Hołowiecki, J., Penka, M., Thiele, J., Kvasnicka, H. M., Královics, R., & Petrides, P. E. (2013) · Blood · doi:10.1182/blood-2012-07-443770 · Cited by 328
Self-citation
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification
Matutes, E., Pickl, W. F., Veer, M. B. V., Morilla, R. M., Swansbury, J. G., Strobl, H., Attarbaschi, A., Hopfinger, G., Ashley, S., Béné, M. C., et al. (2011) · Blood · doi:10.1182/blood-2010-10-314682 · Cited by 325
MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance
Kwok, B., Hall, J., Witte, J. S., Xu, Y., Reddy, P., Lin, K., Flamholz, R., Dabbas, B., Yung, A., Al-Hafidh, J., et al. (2015) · Blood · doi:10.1182/blood-2015-08-667063 · Cited by 322
Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891.
Lange, B. J., Kobrinsky, N. L., Barnard, D., Arthur, D. C., Buckley, J. D., Howells, W. B., Gold, S., Sanders, J. E., Neudorf, S. M. L., Smith, F. O., et al. (1998) · PubMed · doi:10.1182/blood.v91.2.608 · Cited by 303
Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations
Green, C. L., Koo, K., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2501 · Cited by 277
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures
Mendler, J. H., Maharry, K. S., Radmacher, M. D., Mrózek, K., Becker, H., Metzeler, K. H., Schwind, S., Whitman, S. P., Khalife, J., Kohlschmidt, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.6652 · Cited by 277
Self-citation
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis
Schnittger, S., Dicker, F., Kern, W., Wendland, N., Sundermann, J., Alpermann, T., Haferlach, C., & Haferlach, T. (2010) · Blood · doi:10.1182/blood-2009-11-255976 · Cited by 266
Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system
Passmore, S. J., Hann, I. M., Stiller, C. A., Ramani, P., Swansbury, G. J., Gibbons, B., Reeves, B. R., & Chessells, J. M. (1995) · Blood · doi:10.1182/blood.v85.7.1742.bloodjournal8571742 · Cited by 244
A Remote GATA2 Hematopoietic Enhancer Drives Leukemogenesis in inv(3)(q21;q26) by Activating EVI1 Expression
Yamazaki, H., Suzuki, M., Otsuki, A., Shimizu, R., Bresnick, E. H., Engel, J. D., & Yamamoto, M. P. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.008 · Cited by 240
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
Gerstung, M., Pellagatti, A., Malcovati, L., Giagounidis, A. A. N., Porta, M. G. D., Jädersten, M., Dolatshad, H., Verma, A. K., Cross, N. C. P., Vyas, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms6901 · Cited by 237
Self-citation
How I treat juvenile myelomonocytic leukemia
Locatelli, F., & Niemeyer, C. M. (2015) · Blood · doi:10.1182/blood-2014-08-550483 · Cited by 234
Outcome for children and young people with E arly T ‐cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
Patrick, K., Wade, R. L., Goulden, N. J., Mitchell, C., Moorman, A. V., Rowntree, C. J., Jenkinson, S., Hough, R. E., & Vora, A. J. (2014) · British Journal of Haematology · doi:10.1111/bjh.12882 · Cited by 233
Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations
Neumann, M., Heesch, S., Schlee, C., Schwartz, S., Gökbuget, N., Hoelzer, D. F., Konstandin, N. P., Ksienzyk, B., Vosberg, S., Graf, A., et al. (2013) · Blood · doi:10.1182/blood-2012-11-465138 · Cited by 221
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
Tefferi, A., Thiele, J., Vannucchi, A. M., & Barbui, T. (2014) · Leukemia · doi:10.1038/leu.2014.35 · Cited by 216
Self-citation
Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB–Positive Acute Lymphoblastic Leukemia
Weston, B. W., Hayden, M. A., Roberts, K. G., Bowyer, S., Hsu, J. H., Fedoriw, Y. D., Rao, K. W., & Mullighan, C. G. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.6770 · Cited by 212
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
Jabbour, E. J., & Kantarjian, H. M. (2014) · American Journal of Hematology · doi:10.1002/ajh.23691 · Cited by 212
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms
Wang, S. A., Hasserjian, R. P., Fox, P. S., Rogers, H. J., Geyer, J. T., Chabot‐Richards, D., Weinzierl, E. P., Hatem, J., Jaso, J. M., Kanagal‐Shamanna, R., et al. (2014) · Blood · doi:10.1182/blood-2014-02-553800 · Cited by 205
Self-citation
An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome
Harrison, C. J., Moorman, A. V., Schwab, C. J., Carroll, A. J., Raetz, E. A., Devidas, M., Strehl, S., Nebral, K., Harbott, J., Teigler‐Schlegel, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.317 · Cited by 203
Philadelphia Chromosome–Positive Acute Myeloid Leukemia
Soupir, C. P., Vergilio, J., Cin, P. D., Muzikansky, A., Kantarjian, H. M., Jones, D. M., & Hasserjian, R. P. (2007) · American Journal of Clinical Pathology · doi:10.1309/b4nver1ajj84ctuu · Cited by 193
Self-citation
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification
Thiele, J., Kvasnicka, H. M., Müllauer, L., Buxhofer‐Ausch, V., Gisslinger, B., & Gisslinger, H. (2011) · Blood · doi:10.1182/blood-2010-07-293761 · Cited by 182
Self-citation
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations
Meggendorfer, M., Bacher, U., Alpermann, T., Haferlach, C., Kern, W., Gambacorti-Passerini, C. B., Haferlach, T., & Schnittger, S. (2013) · Leukemia · doi:10.1038/leu.2013.133 · Cited by 180
Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression
Cargo, C. A., Rowbotham, N. J., Evans, P., Barrans, S., Bowen, D., Crouch, S., & Jack, A. (2015) · Blood · doi:10.1182/blood-2015-08-663237 · Cited by 179
The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features
Orazi, A., & Germing, U. (2008) · Leukemia · doi:10.1038/leu.2008.119 · Cited by 178
Self-citation
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features
Haferlach, C., Mecucci, C., Schnittger, S., Kohlmann, A., Mancini, M., Cuneo, A., Testoni, N., Rege‐Cambrin, G., Santucci, A., Vignetti, M., et al. (2009) · Blood · doi:10.1182/blood-2009-01-197871 · Cited by 175
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy‐related leukemia
Churpek, J. E., Marquez, R., Neistadt, B., Claussen, K., Lee, M. K., Churpek, M. M., Huo, D., Weiner, H., Banerjee, M., Godley, L. A., et al. (2015) · Cancer · doi:10.1002/cncr.29615 · Cited by 170
Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system
Weinberg, O. K., Seetharam, M., Ren, L., Seo, K., Ma, L., Merker, J. D., Gotlib, J. R., Zehnder, J. L., & Arber, D. A. (2009) · Blood · doi:10.1182/blood-2008-10-182782 · Cited by 165
Self-citation
Clinical significance of early T‐cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children’s Cancer Study Group Study L99‐15
Inukai, T., Kiyokawa, N., Campana, D., Coustan‐Smith, E., Kikuchi, A., Kobayashi, M., Takahashi, H., Koh, K., Manabe, A., Kumagai, M., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08955.x · Cited by 162
Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis
Pabst, T., Eyholzer, M., Fos, J., & Mueller, B. U. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604977 · Cited by 162
Granulocytic sarcoma: a systematic review.
Yılmaz, A. F., Saydam, G., Şahin, F., & Baran, Y. (2013) · Europe PMC (PubMed Central) · Cited by 161
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms
Cazzola, M., Rossi, M., & Malcovati, L. (2012) · Blood · doi:10.1182/blood-2012-09-399725 · Cited by 154
Self-citation
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA
Schlenk, R. F., Taskesen, E., van Norden, Y., Krauter, J., Ganser, A., Bullinger, L., Gaidzik, V. I., Paschka, P., Corbacioglu, A., Göhring, G., et al. (2013) · Blood · doi:10.1182/blood-2013-05-503847 · Cited by 154
Masked polycythemia Vera (mPV): Results of an international study
Barbui, T., Thiele, J., Gisslinger, H., Finazzi, G., Carobbio, A., Rumi, E., Randi, M. L., Betozzi, I., Vannucchi, A. M., Pieri, L., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23585 · Cited by 151
Self-citation
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes
Porta, M. G. D., Travaglino, E., Boveri, E., Ponzoni, M., Malcovati, L., Papaemmanuil, E., Rigolin, G. M., Pascutto, C., Croci, G. A., Gianelli, U., et al. (2014) · Leukemia · doi:10.1038/leu.2014.161 · Cited by 149
Self-citation
T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434
Wood, B. L., Winter, S. S., Dunsmore, K. P., Devidas, M., Chen, S., Asselin, B. L., Esiashvili, N., Loh, M. L., Winick, N. J., Carroll, W. L., et al. (2014) · Blood · doi:10.1182/blood.v124.21.1.1 · Cited by 147
Chronic myelomonocytic leukemia
Bennett, J. M. (2002) · Current Treatment Options in Oncology · doi:10.1007/s11864-002-0011-6 · Cited by 146
Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients
Walter, R. B., Othus, M. K. D., Burnett, A. K., Löwenberg, B., Kantarjian, H. M., Ossenkoppele, G. J., Hills, R. K., van Montfort, K., Ravandi, F., Evans, A., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462440 · Cited by 146
RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant
Ricci, C., Fermo, E., Corti, S. P., Molteni, M., Faricciotti, A., Cortelezzi, A., Deliliers, G. L., Beran, M., & Onida, F. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2112 · Cited by 144
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
Saft, L., Karimi, M., Ghaderi, M., Matolcsy, A., Mufti, G. J., Kulasekararaj, A. G., Göhring, G., Giagounidis, A. A. N., Selleslag, D., Muus, P., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.098103 · Cited by 139
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
Patnaik, M. M., & Tefferi, A. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.5 · Cited by 137
Intrachromosomal Amplification of Chromosome 21 Is Associated With Inferior Outcomes in Children With Acute Lymphoblastic Leukemia Treated in Contemporary Standard-Risk Children's Oncology Group Studies: A Report From the Children's Oncology Group
Heerema, N. A., Carroll, A. J., Devidas, M., Loh, M. L., Borowitz, M. J., Gastier, J. M., Larsen, E. C., Mattano, L. A., Maloney, K. W., Willman, C. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1308 · Cited by 136
Self-citation
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia
Gambacorti-Passerini, C. B., Donadoni, C., Parmiani, A., Pirola, A., Redaelli, S., Signore, G., Piazza, V., Malcovati, L., Fontana, D., Spinelli, R., et al. (2014) · Blood · doi:10.1182/blood-2014-06-579466 · Cited by 129
Self-citation
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
Barbui, T., Thiele, J., Vannucchi, A. M., & Tefferi, A. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.64 · Cited by 128
Self-citation
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
Germing, U., Lauseker, M., Hildebrandt, B., Symeonidis, A. S., Čermák, J., Fenaux, P., Kelaïdi, C., Pfeilstöcker, M., Nösslinger, T., Sekeres, M. A., et al. (2012) · Leukemia · doi:10.1038/leu.2011.391 · Cited by 126
Falini B, Macijewski K, Weiss T, et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood. 2010;115(18):3776–3786.
Falini, B., Macijewski, K., Weiss, T., Bacher, U., Schnittger, S., Kern, W., Kohlmann, A., Klein, H., Vignetti, M., Piciocchi, A., et al. (2010) · Blood · doi:10.1182/blood-2009-08-240457 · Cited by 125
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
Mallo, M., Cervera, J., Schanz, J., Such, E., Garcia‐Manero, G., Luño, E., Steidl, C., Espinet, B., Vallespı́, T., Germing, U., et al. (2010) · Leukemia · doi:10.1038/leu.2010.231 · Cited by 121
Molecular characterization ofde novoPhiladelphia chromosome-positive acute myeloid leukemia
Konoplev, S. N., Yin, C. C., Kornblau, S. M., Kantarjian, H. M., Konopleva, M. Y., Andreeff, M., Lu, G. G., Zuo, Z., Luthra, R., Medeiros, L. J., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.701739 · Cited by 116
Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations
DePersia, A., Godley, L. A., & Churpek, J. E. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12346 · Cited by 114
FLT3 Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitors
Neumann, M., Coskun, E., Fransecky, L. R., Mochmann, L. H., Bartram, I., Sartangi, N. F., Heesch, S., Gökbuget, N., Schwartz, S., Brandts, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053190 · Cited by 108
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification
Hasserjian, R. P., Zuo, Z., Garcia, C. A., Tang, G., Kasyan, A., Luthra, R., Abruzzo, L. V., Kantarjian, H. M., Medeiros, L. J., & Wang, S. A. (2009) · Blood · doi:10.1182/blood-2009-09-243964 · Cited by 108
Self-citation
Clinical and genetic predictors of prognosis in myelodysplastic syndromes
Bejar, R. L. (2014) · Haematologica · doi:10.3324/haematol.2013.085217 · Cited by 107
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
Mughal, T. I., Cross, N. C. P., Padron, E., Tiu, R. V., Savona, M. R., Malcovati, L., Tibes, R., Komrokji, R. S., Kiladjian, J., Garcia-Manero, G., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.114660 · Cited by 102
Self-citation
Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%
Mühlbacher, V., Zenger, M., Schnittger, S., Weißmann, S., Kunze, F., Kohlmann, A., Bellos, F., Kern, W., Haferlach, T., & Haferlach, C. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22163 · Cited by 97
Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis
Barosi, G., Rosti, V., Bonetti, E., Campanelli, R., Carolei, A., Catarsi, P., Isgrò, A. M., Lupo, L., Massa, M., Poletto, V., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035631 · Cited by 96
Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia
Meijerink, J. P. P. (2010) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2010.08.002 · Cited by 92
Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors
Parmentier, S., Schetelig, J., Lorenz, K., Krämer, M., Ireland, R. M., Schuler, U. S., Ordemann, R., Rall, G., Schaich, M. A., Bornhäuser, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.056879 · Cited by 91
Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes
Germing, U., Strupp, C., Giagounidis, A. A. N., Haas, R. R., Gattermann, N., Starke, C., & Aul, C. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.02.014 · Cited by 90
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations
Mallo, M., Rey, M. D., Ibáñez, M., Calasanz, M. J., Arenillas, L., Larráyoz, M. J., Pedro, C., Jerez, A., Maciejewski, J. P., Costa, D., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12354 · Cited by 89
BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures
Boer, J. M., Marchante, J. R. M., We, E., Horstmann, M. A., Escherich, G., Pieters, R., & den Boer, M. L. (2015) · Haematologica · doi:10.3324/haematol.2015.124941 · Cited by 89
Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease
Boiocchi, L., Espinal-Witter, R., Geyer, J. T., Steinhilber, J., Bonzheim, I., Knowles, D. M., Fend, F., & Orazi, A. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.165 · Cited by 87
Self-citation
Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias
Schuler, E., Schroeder, M., Neukirchen, J., Strupp, C., Xicoy, B., Kündgen, A., Hildebrandt, B., Haas, R. R., Gattermann, N., & Germing, U. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.09.003 · Cited by 86
Should myeloid and lymphoid neoplasms with PCM 1‐ JAK 2 and other rearrangements of JAK 2 be recognized as specific entities?
Bain, B. J., & Ahmad, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.12963 · Cited by 84
Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification
Font, P., Loscertales, J., Benavente, C., Bermejo, A., Callejas, M., Garcia-Alonso, L., Garcia-Marcilla, A., Gil, S., López‐Rubio, M., Martin, E., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1565-4 · Cited by 83
Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes
Senent, L., Arenillas, L., Luño, E., Ruíz, J. C., Sanz, G. F., & Florensa, L. (2012) · Haematologica · doi:10.3324/haematol.2012.071449 · Cited by 82
Prognostic irrelevance of ring sideroblast percentage in World Health Organization–defined myelodysplastic syndromes without excess blasts
Patnaik, M. M., Hanson, C. A., Sulai, N. H., Hodnefield, J. M., Knudson, R. A., Ketterling, R. P., Lasho, T. L., & Tefferi, A. (2012) · Blood · doi:10.1182/blood-2012-03-415356 · Cited by 80
Does BCR / ABL 1 positive Acute Myeloid Leukaemia Exist?
Nacheva, E. P., Grace, C. D., Brazma, D., Gancheva, K., Howard‐Reeves, J., Rai, L. J., Gale, R. E., Linch, D. C., Hills, R. K., Russell, N. H., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12301 · Cited by 79
Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia
Hollink, I. H. I. M., van den Heuvel‐Eibrink, M. M., Arentsen-Peters, S. T. C. J. M., Zimmermann, M., Peeters, J. K., Valk, P. J. M., Balgobind, B. V., Sonneveld, E., Kaspers, G. J. L., de Bont, E. S. J. M., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.031336 · Cited by 75
Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome
Roy, A., Roberts, I. A. G., & Vyas, P. (2012) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2012.02.010 · Cited by 74
Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics
Grossmann, V., Bacher, U., Haferlach, C., Schnittger, S., Poetzinger, F., Weißmann, S., Roller, A., Eder, C., Fasan, A., Zenger, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.144 · Cited by 73
Chronic Myelogenous Leukemia, Version 1.2015
O’Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., Curtin, P. T., DeAngelo, D. J., Deininger, M. W., Devine, S. M., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0159 · Cited by 70
Indolent T-Lymphoblastic Proliferation (iT-LBP)
Ohgami, R. S., Arber, D. A., Zehnder, J. L., Natkunam, Y., & Warnke, R. A. (2013) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31828d17ec · Cited by 66
Self-citation
A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification
Verburgh, E. R., Achten, R., Louw, V. J., Brusselmans, C., Delforge, M., Boogaerts, M. A., Hagemeijer, A., Vandenberghe, P., & Verhoef, G. E. G. (2007) · Leukemia · doi:10.1038/sj.leu.2404564 · Cited by 66
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity
Bacher, U., Schnittger, S., Macijewski, K., Großmann, V., Kohlmann, A., Alpermann, T., Kowarsch, A., Nadarajah, N., Kern, W., Haferlach, C., et al. (2012) · Blood · doi:10.1182/blood-2011-12-395574 · Cited by 65
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
Gisslinger, H., Jeryczynski, G., Gisslinger, B., Wölfler, A., Burgstaller, S., Buxhofer‐Ausch, V., Schalling, M., Krauth, M.-T., Schiefer, A.-I., Kornauth, C., et al. (2015) · Leukemia · doi:10.1038/leu.2015.360 · Cited by 63
Self-citation
Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification
van den Ancker, W., Terwijn, M., Westers, T. M., Merle, P. A., van Beckhoven, E., Dräger, A. M., Ossenkoppele, G. J., & van de Loosdrecht, A. A. (2010) · Leukemia · doi:10.1038/leu.2010.119 · Cited by 62
Philadelphia chromosome‐positive mixed phenotype acute leukemia in the imatinib era
Shimizu, H., Yokohama, A., Hatsumi, N., Takada, S., Handa, H., Sakura, T., & Nojima, Y. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12343 · Cited by 62
Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms
Gianelli, U., Bossi, A., Cortinovis, I., Sabattini, E., Tripodo, C., Boveri, E., Moro, A., Valli, R., Ponzoni, M., Florena, A. M., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.196 · Cited by 61
World Health Organization‐defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations—The Danish experience
Madelung, A. B., Bondo, H., Stamp, I. M., Loevgreen, P., Nielsen, S. L., Lauritzen, A. M. F., Knudsen, H., Ehinger, M., Dahl‐Sørensen, R. B., Mortensen, N. B., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23554 · Cited by 60
Self-citation
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene
Rumi, E., Feenstra, J. D. M., Selleslag, D., Casetti, I. C., Lierman, E., Pietra, D., Cavalloni, C., Bellini, M., Milanesi, C., Dambruoso, I., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2451-7 · Cited by 60
Self-citation
Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics
Wang, S. A., & Hasserjian, R. P. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcprkyat6ezqhc7 · Cited by 52
Self-citation
Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1
Patterer, V., Schnittger, S., Kern, W., Haferlach, T., & Haferlach, C. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1695-3 · Cited by 51
Myeloproliferative neoplasms: Morphology and clinical practice
Barbui, T., Thiele, J., Vannucchi, A. M., & Tefferi, A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24288 · Cited by 50
Self-citation
Diagnosis and management of mastocytosis: an emerging challenge in applied hematology
Valent, P. (2015) · Hematology · doi:10.1182/asheducation-2015.1.98 · Cited by 48
Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia
Cervera, N., Itzykson, R., Coppin, E., Prébet, T., Murati, A., Legall, S., Vey, N., Solary, É., Birnbaum, D., & Gelsi‐Boyer, V. (2014) · American Journal of Hematology · doi:10.1002/ajh.23702 · Cited by 46
Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts
MAASSEN, A. P., Strupp, C., Giagounidis, A. A. N., Kuendgen, A., Nachtkamp, K., Hildebrandt, B., Gattermann, N., Aul, C., Haas, R. R., & Germing, U. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.09.021 · Cited by 46
The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status
Díaz‐Beyá, M., Rozman, M., Pratcorona, M., Torrebadell, M., Camós, M., Aguilar, J. L., & Esteve, J. (2010) · Blood · doi:10.1182/blood-2010-09-307314 · Cited by 46
A new prognostic score for CLL
Tam, C. S. L., & Seymour, J. F. (2014) · Blood · doi:10.1182/blood-2014-05-575407 · Cited by 34
Reply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis’
Hou, H.-A., Lin, L., Chen, C.-Y., & Tien, H. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605207 · Cited by 34
Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications
Boiocchi, L., Gianelli, U., Iurlo, A., Fend, F., Bonzheim, I., Cattaneo, D., Knowles, D. M., & Orazi, A. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.100 · Cited by 32
Self-citation
Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML
Zuo, Z., Medeiros, L. J., Chen, Z., Liu, D., Bueso-Ramos, C., Luthra, R., & Wang, S. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041485 · Cited by 30
Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1
on behalf of Grup Català de Citologia Hematològica and Spanish CETLAM Group (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas), Rozman, M., Navarro, J., Arenillas, L., Aventin, A. M., Giménez, T., Alonso, E., Perea, G., Camós, M., Navarrete, M., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2100-6 · Cited by 29
Diagnosing and Managing Advanced Chronic Myeloid Leukemia
Deininger, M. W. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e381 · Cited by 28
CML—where do we stand in 2015?
Hehlmann, R. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2331-1 · Cited by 27
Deregulation of Genes Related to Iron and Mitochondrial Metabolism in Refractory Anemia with Ring Sideroblasts
Rey, M. D., Benito, R., Fontanillo, C., Campos-Laborie, F. J., Janusz, K., Velasco-Hernández, T., Abáigar, M., Hernández‐Sánchez, M., Cuello, R., Borrego, D., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126555 · Cited by 23
Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status
Kawajiri, C., Tanaka, H., Hashimoto, S., Takeda, Y., Sakai, S., Takagi, T., Takeuchi, M., Ohwada, C., Sakaida, E., Shimizu, N., et al. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1531-0 · Cited by 22
Acute myeloid leukemia with expanded erythropoiesis
Porwit‐MacDonald, A., & Vardiman, J. (2011) · Haematologica · doi:10.3324/haematol.2011.050526 · Cited by 16
Self-citation
Chronic Myelomonocytic Leukemia
Maslak, P. G. (2004) · ASH Image Bank · doi:10.1182/ashimagebank-2004-101198 · Cited by 2

Sorted by citations

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,938
Self-citation
WHO classification of haematolymphoid tumours
Gaillard, F., & Gerstenmaier, J. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,763
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., Dinardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,633
Self-citation
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood · doi:10.1182/blood.2022015850 · Cited by 2,945
Self-citation
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612

See all 10,119

Authors: Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W.
Affiliations: Stanford Medicine (US)
Weill Cornell Medicine (US)
Massachusetts General Hospital (US)
University of Cologne (DE)
Johns Hopkins Medicine (US)
Section of Hematology/Oncology, University of Chicago, Chicago, IL;
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
University of Pavia (IT)
University of Chicago (US)
ORCID: Arber, Daniel A.
Orazi, Attilio
Hasserjian, Robert
Bloomfield, Clara D.
Cazzola, Mario
Venue: Blood
Publisher: American Society of Hematology
Published: 2016-05-19
Volume: 127
Issue: 20
Pages: 2391-2405
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2016-03-643544
OpenAlex: W2339658711
Cited by: 10,119
References: 139
Citations by year: 2026: 370 · 2025: 615 · 2024: 875 · 2023: 1132 · 2022: 1265 · 2021: 1424 · 2020: 1187 · 2019: 998 · 2018: 954 · 2017: 797 · 2016: 320
FWCI: 145.41
Type: journal article
Language: en
Update notices: erratum (2016-07-21)
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
Funders: Celgene
Incyte
Sysmex Corporation
Genentech
Takeda Oncology
Pharmacyclics
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
Keywords: WHO classification of hematologic neoplasms, myeloid neoplasms, acute leukemia, diagnostic criteria, prognostic factors, gene expression profiling, next-generation sequencing, immunophenotyping, morphological classification, new disease entity
MeSH terms: Down Syndrome, Eosinophilia, Humans, Leukemia, Myeloid, Mastocytosis, Myelodysplastic Syndromes, Myeloproliferative Disorders, World Health Organization, Oncogene Proteins, Fusion, Cell Lineage, Myeloid Cells, Genes, Neoplasm, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks